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PRAME gene expression profile 
in medulloblastoma
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ABSTRACT
Medulloblastoma is the most common malignant tumors of central nervous system in the 
childhood. The treatment is severe, harmful and, thus, has a dismal prognosis. As PRAME is 
present in various cancers, including meduloblastoma, and has limited expression in normal 
tissues, this antigen can be an ideal vaccine target for tumor immunotherapy. In order to 
find a potential molecular target, we investigated PRAME expression in medulloblastoma 
fragments and we compare the results with the clinical features of each patient. Analysis 
of gene expression was performed by real-time quantitative PCR from 37 tumor samples. 
The Mann-Whitney test was used to analysis the relationship between gene expression 
and clinical characteristics. Kaplan-Meier curves were used to evaluate survival. PRAME 
was overexpressed in 84% samples. But no statistical association was found between 
clinical features and PRAME overexpression. Despite that PRAME gene could be a strong 
candidate for immunotherapy since it is highly expressed in medulloblastomas.
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Perfil de expressão do gene PRAME em meduloblastoma
RESUMO
Meduloblastoma é o tumor maligno mais comum em sistema nervoso central na infância. 
O tratamento é agressivo e o prognóstico é restrito. Como PRAME está presente em vários 
tumores, incluindo meduloblastoma, e possui baixa expressão em tecidos normais, este 
antígeno pode ser ideal na imunoterapia. A fim de encontrar um potencial alvo molecular, 
investigamos a expressão PRAME em fragmentos de meduloblastoma e comparamos os 
resultados com as características clínicas de cada paciente. Análise da expressão do gene 
foi realizada por PCR real-time quantitativo em 37 amostras de tumor. O teste de Mann-
Whitney foi utilizado para análise da relação entre a expressão do gene e características 
clínicas e teste de Kaplan-Meier para avaliar a sobrevida. PRAME teve superexpresssão em 
84% amostras, mas não houve nenhuma relação estatística entre as características clínicas 
e superexpressão de PRAME. Apesar disso, o gene PRAME poderia ser um forte candidato 
para a imunoterapia, pois é altamente expresso em meduloblastomas.
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Medulloblastoma (MB) is the most 
common malignant tumors of central ner-
vous system (CNS) and is a tumor high-
ly aggressive1-3. Despite of the multimod-
al therapeutic regimens involving sur-
gery, radiotherapy and chemoratherapy, 
the treatment carries a dismal prognosis 
and frequently results in neurological de-
velopment and growth deficit, and endo-
crine dysfunction1,2. 
Over the decades, several categories 
of antigens were found, including unique-
ly mutated antigens (e.g. p53), viral an-
tigens (e.g. human papillomavirus anti-
gens in cervical cancer), and differentia-
tion antigens (e.g. CD20 in B-cell lympho-
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ma). More recently, a new category of antigen, namely the 
cancer ⁄ testis (CT) antigen, has emerged to be a unique 
group of antigen that could potentially be important an-
tigen targets for antigen-specific cancer immunothera-
py. For tumor antigens to be potential immunotherapeu-
tic targets, the antigen must have no or highly restricted 
expression in normal tissues so that autoimmunity can 
be prevented4. 
Currently, researches have been focused in the iden-
tification of tumor antigens in order to develop efficient 
therapeutic strategy. The new strategy is find ideal tumor 
antigens to apply as vaccine targets for immunotherapy5. 
However, it is still rare to find a suitable antigen for spe-
cific targeting and its identification remains a hard task. 
Immunotherapy against brain tumors presents unique 
challenges since the brain is considered an immune priv-
ileged site. However, recent studies demonstrated that 
the immune cells have access to the brain in spite of the 
blood-brain barrier6,7. Within malignant brain tumors the 
blood-brain barrier is generally considered non-function-
al. Progress, in our understanding, of immune responses 
to CNS tumors have already led to novel clinical appli-
cations8. Immunotherapy is an attractive therapeutic op-
tion for pediatric cancer patients because of its mild tox-
icity, and because the child’s immune system is more po-
tent and flexible compared to adults9,10. However, imple-
mentation of immunotherapy in pediatric oncology has 
been hampered by the lack of known tumor-specific an-
tigens on pediatric tumors11.
One of these antigens, much studied in leukemia12-17, 
is tumor antigen PRAME (Preferentially Expressed Anti-
gen in Melanoma). It was first discovered in a patient with 
melanoma and it was responsible for triggering cytotox-
ic T-cell-mediated immune response by autologous lym-
phocytes18. PRAME is frequently express in several sol-
id tumors including neuroblastoma and medulloblasto-
ma, but not or weak in normal tissues19,20. In neuroblas-
toma, PRAME expression is very commom and its over-
expression is associated with advanced disease stage and 
poor prognostic20. 
The aim of this study was to analyze PRAME gene ex-
pression in pediatric MB. We report the results of a quan-
titative real-time PCR analysis of the PRAME expression 
and compare with the clinical features of these patients.
METHOD
Patients
We selected 37 MBs samples from patients (medi-
an age: 8 years) attending the Pediatric Oncology Insti-
tute (IOP)/Grupo de Apoio ao Adolescente e a Criança 
com Câncer (GRAACC) - Federal University of São Pau-
lo (UNIFESP) - Brazil. Two normal brain samples, unre-
lated to pathological condition served as a tissue-specific 
expression control. Informed consent was obtained from 
all patients/guardians according to the University’s IRB 
(CEP/UNIFESP Nº1120/01). All MB patients were clas-
sified according to Chang et al.21, as follows: M stage in-
clude M0 (no evidence of disseminated disease), M1 (tu-
mor cells identified by cerebrospinal fluid (CSF) cytolo-
gy only), M2 (intracranial metastatic tumor detectable 
by computed tomography (CT) or magnetic resonance 
imaging (MRI) and M3 (spinal metastatic tumor detect-
able by CT myelography or spine MRI); and the current 
WHO (World Health Organization) classification of CNS 
tumors was used to define the following histopathological 
variants of medulloblastoma: classic, desmoplastic/ nod-
ular, anaplasic and large-cell medulloblastoma22.
RNA extraction and cDNA synthesis
Total RNA was isolated from frozen samples pulver-
ized under nitrogen liquid and extracted using TRIzol 
reagent (Invitrogen, Carlsbad, CA, USA). To reduce the 
risk of genomic DNA contamination, DNase treatment 
was performed using deoxyribonuclease I Amplification 
Grade (Invitrogen, Carlsbad, CA, USA). The concentra-
tion of RNA was determined by spectrophotometry and 
total RNA integrity was monitored by visualization of ri-
bosomal RNAs (28S and 18S) on 1% agarose gel. One 
microgram of total RNA derived from 37 MB samples 
was reverse-transcribed using the SuperScript III Reverse 
Transcriptase Kit (Invitrogen, Carlsbad, CA, USA) ac-
cording to the manufacturer’s instructions.
Quantitative Real-Time RT-PCR
Oligonucleotides for PRAME and the endogenous 
gene, HPRT, were designed using Primer Express Soft-
ware from Applied Biosystems (Foster City, CA, USA), 
warranting that forward and reverse sequences were in 
different exons. Primer sequences were as follows (5’ - 
3’): PRAME Forward: CTGTACTCATTTCCAGAGC-
CAGA, PRAME Reverse: TATTGAGAGAGGGTTTC-
CAAGGGGTT, HPRT (hypoxanthine-guanine phos-
phoribosyl transferase) Forward: TGAGGATTTG-
GAAAGGGTGT and HPRT Reverse: GAGCACA-
CAGAGGGCTACAA. 
We conducted a BLAST search to confirm the total 
gene specificity of the nucleotide sequences chosen for 
primers. Real-time PCR amplification and data analy-
sis were performed using the ABI Prism 7500 Sequence 
Detector System Applied Biosystems (Foster City, CA, 
USA). Each cDNA sample was mixed with 12 µl of Mas-
termix (SYBR® Green PCR Master Mix, Applied Biosys-
tems). Cycling conditions consisted of two singles steps at 
50ºC and 95ºC for 2min and 10min respectively, followed 
by 40 cycles of amplification at 95ºC for 15s and at 60ºC 
for 1min for annealing and elongation. Experiments were 
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performed in triplicate for both target genes and the en-
dogenous gene. For each sequence, a standard curve was 
constructed to determine the assay sensitivity. The data 
were averaged from the values obtained in each reaction. 
Relative expression was automatically calculated and an-
alysed according to 2-∆∆Ct method described previously23. 
Relative quantification describes a real-time PCR exper-
iment in which the gene of interest (PRAME) in one tu-
mor sample is compared to same gene in normal tissue, 
as expression calibrator. HPRT was used as a housekeep-
ing gene to normalize the relative expression level to pro-
vide an accurate comparison of gene expression between 
different samples. Expression of the housekeeping gene 
HPRT served as an endogenous control in each assay per-
formed. The PCR efficiencies of the two genes were com-
parable (≥95%).
Statistical analysis
Statistical analyses were carried out using Graph Pad 
Prism 4 Program (San Diego, CA, USA). The t test was 
used to analyze the gene expression of each gene stud-
ied. The Mann-Whitney test was used to analysis the re-
lationship between gene expressions and clinical charac-
teristics. In all cases, p<0.05 was considered statistical-
ly significant. Kaplan-Meier curves were used to evalu-
ate survival.
RESULTS
All clinical variables are summarized in Table. Stages 
M1, M2 and M3 were included in just one group named 
M+, 32% (n=12). In the M stage we found: stage M0, 68% 
(n=25), stage M1, 6% (n=2), stage M2, 13% (n=5) and M3, 
13% (n=5). Eighteen of 37 patients died from disease and 
19 patients were disease-free or in treatment. The most of 
our samples were classic medulloblastoma (92%). 
PRAME was overexpressed in 31 (84%) samples, me-
dian 33 (p=0.08) (cut-off ≥2) (Figure). The differentially 
expressed genes were determined based on two criteria: 
gene performance outline filtering was applied to exclude 
the lower intensity or absent values, and only genes with 
fold changes larger than –2 and +2 were considered for in-
creased/ decreased expression. Seventeen of 31 (55%) was 
high risk, two (6%) was anaplastic or large-cell/anaplastic 
subtype, 9 (29%) was relapsed, 16 (52%) were died, 8 (26%) 
were metastatic (M+) stage, beyond that 12 (39%) suf-
fered partial resection of tumor. No statistical association 
was found between clinical features and PRAME expres-
sion. Likewise, there were no significant association with 
PRAME expression and Kaplan-Meier survival curves.
DISCUSSION
Medulloblastoma is the most common malignancy in 
children and it is highly aggressive3. In spite of the sophis-
ticated techniques of neurosurgery, radiotherapy and che-
motherapy, this tumor has a high mortality rate2,24 and the 
most of the survivors suffer from neurological develop-
ment and growth deficit, and endocrine dysfunction1,25. 
The identification of tumor-specific antigens, as 
PRAME, can be an essential step in toward to cancer 
vaccines. PRAME is frequently expressed in melanomas, 
non-small cell lung carcinoma, breast carcinoma, renal 
cell carcinoma, head and neck cancer, Wilms’ tumor and 
Hodgkin’s lymphoma12,14,17-19. PRAME overexpression, in 
some type of solid tumors, is associated with aggressive-
ness of the tumor and poor clinical outcome18-21,26. 
Usually gene expression profile can provide the key 
Table. Clinical variable evaluated.
Clinical variable Patients (%)
Classification
   High risk 57
   Low risk 43
Stage
   M0 67
   M+ 32
Surgery
   Total 54
   Partial 46
Follow-up
   Death 57
   Out or in treatment 43
Relapse
   Relapsed 26
   Non relapsed 74
M0: no evidence of disseminated disease; M+: evidence of disseminated 
disease.
Figure. Representative results of PRAME expression for all 
samples studied. The PRAME expression in medulloblastoma 
fragments not showed statistical significance in relation to refer-
ence RNA (p=0.08). Black line is the median. Dotted line repre-
sents normal samples.
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toward to find good tumor markers, hence we verified 
the gene expression of PRAME in MB samples by Real-
time RT-PCR technique and compared the results with 
some clinical features. Although we did not have find any 
correlation between PRAME expression and the clinical 
variable studied, we find that 84% of patients presented 
high PRAME expression. We could not detect a correla-
tion between PRAME expression in the tumor and clin-
icopathological parameters of the patients. Jacobs et al.28 
proposed that vaccination of patients with tumor anti-
gens is conceivable at all disease stages, including when a 
large tumor burden is present. Furthermore, considering 
that pediatric tumors tend to coexpress multiple antigen 
tumors, one may target several antigens in the same pa-
tient, which should reduce the risk of resistance through 
antigen-loss tumor variants27,28.
In general, it is rare to find data that allow clear asso-
ciation between expression of tumor-associated antigens 
and the outcome of patients29,30. Nevertheless, associa-
tion of tumor-associated antigens with advanced diseas-
es has been showed in a couple of studies29-30. Taken to-
gether, all this information plus our results, we can sug-
gest that the remarkably higher levels of PRAME expres-
sion found in our samples can be an evidence of possi-
ble target therapeutic in cancer vaccines in medulloblas-
toma patients. However, the question about the ability of 
the patients to cause an immunological response to this 
antigen remains unknown.
Although there was no association between PRAME 
expression and clinical features of patients, PRAME gene 
could be a candidate for immunotherapy target using 
antibodies or inhibiter small molecules like anti-cancer 
agents, since it is highly expressed in medulloblastomas.
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